Alkermes to present data on new medicines in development for schizophrenia and depression

Results of positive Phase 3 study for aripiprazole lauroxil in schizophrenia to be presented at upcoming American Society of Clinical Psychopharmacology Annual Meeting

Alkermes is to present the data from studies of the company’s pipeline of drug candidates in schizophrenia and depression at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Hollywood, Florida, 16-19 June 2014.

Schizophrenia

Comprehensive data from the recently completed Phase 3 study of aripiprazole lauroxil in patients with schizophrenia will be presented. The ASCP scientific committee has nominated this data presentation as a best poster, which will appear in the online 2014 ASCP Poster Session.

Wednesday, 18 June 2014, 12:00 – 2:00 p.m. ET

Poster 75: Safety and Efficacy of Aripiprazole Lauroxil: Results From a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Acute Exacerbation of Schizophrenia.

Alkermes will also present data related to the company’s state-of-the-art clinical trial methodologies in schizophrenia as well as data pertaining to the company’s development of ALKS 3831, a new investigational medication designed to address important unmet medical needs of patients with schizophrenia.

Tuesday, 17 June 2014, 3:30 – 4:30 p.m. ET

The oral presentation, “Analysis and Missing Data Handling in Psychiatry Trials With Inevitable, High, Differential and Informative Discontinuations,” will be presented during a symposium entitled, “Statistical Methods, Personality Disorders, Substance Abuse, and Comorbidity Presentations.”

Wednesday, 18 June 2014, 12:00 – 2:00 p.m. ET

Poster 73: Prevalence, Healthcare Utilization and Cost of Patients Dual Diagnosed With Schizophrenia and an Alcohol Use Disorder.

Depression

Data relating to ALKS 5461, the company’s development candidate for the treatment of major depressive disorder (MDD), will be presented. This presentation has also been nominated as a best poster, and will appear in the online 2014 ASCP Poster Session.

Tuesday, 17 June, 2014, 11:15 a.m. – 1:00 p.m. ET

Poster 44: ALKS 5461, a Novel Opioid Modulator as Adjunctive Treatment for Depression.

Alkermes will also present data related to the company’s state-of-the-art clinical trial methodologies in depression. Key presentations include:

Wednesday, 18 June, 2014, 12:00 – 2:00 p.m. ET

Poster 26: Feasibility, Integrity and Efficiency of the Sequential Parallel Comparison Clinical Trial Design.

Poster 27: Blinded Dual Ratings Confirm Primary Site-Based Ratings in an MDD Trial.

A full list of all Alkermes abstracts being presented at the ASCP meeting is available at: http://ascpmeeting.org/.

Companies